Exzeo Group, Inc. (XZO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on November 4, 2025, and November 6, 2025. Exzeo Group, Inc., a Florida corporation, reported the completion of an underwritten public offering of common stock and the subsequent listing of its shares on the New York Stock Exchange (NYSE) under the symbol "XZO". The company is classified as an emerging growth company.
Key Financial Metrics and Capital Structure
- Offering Size: 8,000,000 shares of Common Stock sold at $21.00 per share.
- Gross Proceeds: Approximately $168,000,000 (before underwriting discounts, commissions, and offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 1,200,000 shares.
- Lock-Up Agreements: Officers, directors, and majority shareholder HCI Group, Inc. agreed to an 180-day lock-up period restricting the sale or transfer of securities.
- Operating Metrics: The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes
The primary material change is the transition to a publicly traded entity via the Public Offering. The company amended and restated its Articles of Incorporation and Bylaws effective November 6, 2025, in connection with the offering. Trading of the Common Stock commenced on the NYSE on November 5, 2025.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the offering pricing and closing. The Underwriting Agreement includes customary representations, warranties, and covenants, along with indemnification provisions for the underwriters. The filing notes that the information provided in the press releases (Exhibits 99.1 and 99.2) is not deemed "filed" for purposes of Section 18 of the Exchange Act. No specific forward-looking guidance or risk factors beyond standard underwriting terms are detailed in this specific 8-K text.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting discounts and estimated offering expenses.
- Review the full text of the Underwriting Agreement (Exhibit 1.1 to the Registration Statement) for specific covenants and indemnification details.
- Confirm the terms of the 30-day over-allotment option and whether it has been exercised.
- Examine the Fourth Amended and Restated Articles of Incorporation (Exhibit 3.1) for changes to capital structure or governance.
- Check the final prospectus filed on November 5, 2025, for a detailed description of the capital stock and risk factors.